• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers.克唑替尼作为晚期ALK阳性非小细胞肺癌的一线治疗药物。
Transl Lung Cancer Res. 2015 Oct;4(5):639-41. doi: 10.3978/j.issn.2218-6751.2015.03.06.
2
Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.非小细胞肺癌的靶向治疗：聚焦于ALK/ROS1酪氨酸激酶抑制剂
Expert Rev Anticancer Ther. 2018 Jan;18(1):71-80. doi: 10.1080/14737140.2018.1412260. Epub 2017 Dec 6.
3
Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives.克唑替尼用于ALK阳性晚期非小细胞肺癌一线治疗的聚焦：患者选择与前景
Lung Cancer (Auckl). 2016 Jun 17;7:83-90. doi: 10.2147/LCTT.S99303. eCollection 2016.
4
Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic.克唑替尼治疗对捷克共和国ALK易位非小细胞肺癌的影响。
Klin Onkol. 2018 Spring;31(3):207-212. doi: 10.14735/amko2018207.
5
Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC.克唑替尼在一线治疗ALK阳性晚期非小细胞肺癌成人患者中的疗效。
Expert Opin Pharmacother. 2016 Aug;17(12):1693-701. doi: 10.1080/14656566.2016.1208171. Epub 2016 Jul 13.
6
Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.EML4-ALK 融合检测及一线克唑替尼治疗对晚期 ALK 阳性非小细胞肺癌患者的成本效果分析。
J Clin Oncol. 2014 Apr 1;32(10):1012-9. doi: 10.1200/JCO.2013.53.1186. Epub 2014 Feb 24.
7
New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.间变性淋巴瘤激酶阳性非小细胞肺癌的新见解
Indian J Cancer. 2017 Jan-Mar;54(1):203-208. doi: 10.4103/ijc.IJC_72_17.
8
Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance.ALK 阳性晚期非小细胞肺癌患者克唑替尼耐药后生存的有利预测因素。
Thorac Cancer. 2019 May;10(5):1096-1102. doi: 10.1111/1759-7714.13050. Epub 2019 Mar 28.
9
Crizotinib in the treatment of non--small-cell lung cancer.克唑替尼治疗非小细胞肺癌。
Clin Lung Cancer. 2013 Sep;14(5):473-80. doi: 10.1016/j.cllc.2013.04.006. Epub 2013 Jun 20.
10
Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients.克唑替尼进展的监测与特征分析：ALK阳性非小细胞肺癌患者的图表回顾
Adv Ther. 2017 Jul;34(7):1673-1685. doi: 10.1007/s12325-017-0551-6. Epub 2017 Jun 3.

引用本文的文献

1
Successful management of an unusual case of pediatric inflammatory myofibroblastic tumor: a case report and literature review.小儿炎性肌纤维母细胞瘤罕见病例的成功管理：一例报告及文献综述
Ann Med Surg (Lond). 2025 Jan 9;87(1):407-412. doi: 10.1097/MS9.0000000000002870. eCollection 2025 Jan.
2
'Plasma first' approach for detecting epidermal growth factor receptor mutation in advanced non-small cell lung carcinoma.'血浆优先'方法检测晚期非小细胞肺癌中的表皮生长因子受体突变。
J Cancer Res Clin Oncol. 2024 Jul 27;150(7):371. doi: 10.1007/s00432-024-05828-w.
3
Natural Product-Based Glycolysis Inhibitors as a Therapeutic Strategy for Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.基于天然产物的糖酵解抑制剂作为治疗表皮生长因子受体酪氨酸激酶抑制剂耐药的非小细胞肺癌的策略。
Int J Mol Sci. 2024 Jan 9;25(2):807. doi: 10.3390/ijms25020807.
4
Augmented drug combination dataset to improve the performance of machine learning models predicting synergistic anticancer effects.增强型药物组合数据集，提高机器学习模型预测协同抗癌效果的性能。
Sci Rep. 2024 Jan 18;14(1):1668. doi: 10.1038/s41598-024-51940-9.
5
First case report of a novel KIF13A-ALK fusion in a lung adenocarcinoma patient and response to alectinib with a 4-year follow-up.首例肺腺癌患者中新型KIF13A-ALK融合的病例报告及对阿来替尼的4年随访反应
Front Genet. 2023 Dec 13;14:1289346. doi: 10.3389/fgene.2023.1289346. eCollection 2023.
6
Augmented drug combination dataset to improve the performance of machine learning models predicting synergistic anticancer effects.增强型药物组合数据集，以提高预测协同抗癌效果的机器学习模型的性能。
Res Sq. 2023 Oct 28:rs.3.rs-3481858. doi: 10.21203/rs.3.rs-3481858/v1.
7
LTK and ALK promote neuronal polarity and cortical migration by inhibiting IGF1R activity.LTK 和 ALK 通过抑制 IGF1R 活性促进神经元极性和皮质迁移。
EMBO Rep. 2023 Jul 5;24(7):e56937. doi: 10.15252/embr.202356937. Epub 2023 Jun 9.
8
Alectinib for treating patients with metastatic -positive NSCLC: systematic review and network metanalysis.阿来替尼治疗转移性阳性非小细胞肺癌患者：系统评价和网状Meta分析
Lung Cancer Manag. 2023 May 23;12(2):LMT59. doi: 10.2217/lmt-2022-0018. eCollection 2023 Jun.
9
Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives.循环肿瘤DNA（ctDNA）在癌基因驱动的非小细胞肺癌中的预后价值：当前认知与未来展望
Cancers (Basel). 2022 Oct 10;14(19):4954. doi: 10.3390/cancers14194954.
10
Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies.间变性淋巴瘤激酶（ALK）和ROS1重排肺癌的转移方式、潜在机制及当前可能的治疗策略
RSC Adv. 2019 Jun 7;9(31):17921-17932. doi: 10.1039/c9ra02258a. eCollection 2019 Jun 4.

本文引用的文献

1
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.克唑替尼对比化疗用于治疗 ALK 阳性肺癌。
N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440.
2
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.克唑替尼耐药的间变性淋巴瘤激酶（ALK）重排非小细胞肺癌（NSCLC）患者中艾乐替尼针对全身疾病和脑转移的安全性和活性：一项 1/2 期研究剂量探索部分的结果。
Lancet Oncol. 2014 Sep;15(10):1119-28. doi: 10.1016/S1470-2045(14)70362-6. Epub 2014 Aug 18.
3
Ceritinib in ALK-rearranged non-small-cell lung cancer.塞瑞替尼治疗间变性淋巴瘤激酶重排的非小细胞肺癌。
N Engl J Med. 2014 Mar 27;370(13):1189-97. doi: 10.1056/NEJMoa1311107.
4
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.重点：培美曲塞维持治疗对比安慰剂用于培美曲塞联合顺铂诱导治疗后晚期非鳞状非小细胞肺癌的 III 期研究的最终总生存结果。
J Clin Oncol. 2013 Aug 10;31(23):2895-902. doi: 10.1200/JCO.2012.47.1102. Epub 2013 Jul 8.
5
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.III 期研究阿法替尼或顺铂加培美曲塞治疗 EGFR 突变的转移性肺腺癌患者。
J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1.
6
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.克唑替尼与化疗用于治疗晚期 ALK 阳性肺癌。
N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1.
7
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.克唑替尼（RO5424802）治疗间变性淋巴瘤激酶（ALK）重排的晚期非小细胞肺癌患者（AF-001JP 研究）：一项单臂、开放标签、1 期和 2 期研究。
Lancet Oncol. 2013 Jun;14(7):590-8. doi: 10.1016/S1470-2045(13)70142-6. Epub 2013 Apr 30.
8
Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement.ALK 基因重排阳性肺癌患者中枢神经系统孤立进展后继续克唑替尼治疗的临床影响。
J Thorac Oncol. 2013 May;8(5):654-7. doi: 10.1097/JTO.0b013e31828c28e7.
9
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.厄洛替尼对比标准化疗用于治疗欧洲晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗（EURTAC）：一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.
10
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.克唑替尼治疗携带 ALK 基因重排的晚期非小细胞肺癌患者的总生存影响：一项回顾性分析。
Lancet Oncol. 2011 Oct;12(11):1004-12. doi: 10.1016/S1470-2045(11)70232-7. Epub 2011 Sep 18.

Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers.

作者信息

Chuang Jody C, Neal Joel W

机构信息

1 Division of Hematology and Oncology, Stanford Hospital & Clinics, Stanford, CA, USA ; 2 Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.

出版信息

Transl Lung Cancer Res. 2015 Oct;4(5):639-41. doi: 10.3978/j.issn.2218-6751.2015.03.06.

DOI:10.3978/j.issn.2218-6751.2015.03.06
PMID:26629437
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4630528/
Abstract
摘要